IQVIA posts Q4 2025 revenue of USD 4.36 billion, up 10%

Reuters
Feb 05
IQVIA posts Q4 2025 revenue of USD 4.36 billion, up 10%

IQVIA reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Revenues for Q4 reached USD 4.36 billion, with net income attributable to shareholders at USD 514 million. For the full year 2025, revenues totaled USD 16.31 billion, while net income attributable to shareholders was USD 1.36 billion. Diluted earnings per share for Q4 stood at USD 2.99, and at USD 7.84 for the full year. The company highlighted strong performance across all segments, with near double-digit growth in revenue and earnings per share for 2025. IQVIA noted the strongest quarter of the year in Research & Development Solutions net bookings and cited the benefits of its expanded go-to-market strategy, operational discipline, and investments in artificial intelligence innovations. Management indicated that these factors contributed to clear differentiation and robust topline growth in both the commercial and clinical businesses during the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IQVIA Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205999087) on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10